Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Tuberculosis and Neglected Diseases Targeted by New Centre

Published: Thursday, February 14, 2013
Last Updated: Thursday, February 14, 2013
Bookmark and Share
New centre to boost the development of drugs to tackle diseases of the developing world.

A major new centre to boost the development of drugs to tackle the foremost diseases of the developing world is to be created at the University of Dundee.

There is an urgent need for new drugs to treat infectious diseases of the developing world, such as tuberculosis (TB), malaria and African sleeping sickness.

However, despite significant efforts in early stage drug discovery, there is a bottleneck when it comes to the lead optimization stage of molecules targeting these diseases.

Lead optimization is a key stage in the drug discovery process, where early leads are improved through cycles of design, synthesis and testing to identify potential drugs which are suitable for testing in a clinical setting. It is a labour intensive process requiring significant laboratory resource over a number of years.

To address this need Professor Paul Wyatt and colleagues at the Drug Discovery Unit (DDU) at the University of Dundee, with joint funding from the Wellcome Trust and the Bill & Melinda Gates Foundation, are establishing “A Centre of Excellence for Lead Optimization for Diseases of the Developing World”.

The Dundee centre represents a £6.5million investment over five years and will create 11 new posts.

Professor Wyatt said, “One of the main aims of the Drug Discovery Unit is to make inroads into developing drugs for diseases that affected the developing world. We have the capability through the DDU to help break the bottleneck which occurs at a key stage of the drug discovery process.”

The initial focus will be on TB, the world’s second-leading infectious killer, disproportionately affecting developing countries; in 2010 causing 1.4 million deaths, 8.8 million new infections and 450 thousand drug-resistant TB cases.

First-line therapies for TB are old and inadequate, taking six months to cure patients. The long treatment regimen contributes to high treatment default rates that can lead to increased disease transmission, drug resistance, and death.

The strategy is to identify a portfolio of TB Lead Optimization projects through the DDU’s involvement with the global HIT-TB consortium and TB Drug Accelerator Program which are working to generate drug leads through their screening programmes.

The DDU as part of HIT-TB is already identifying and optimizing multiple series of related compounds which kill TB that could be taken up by the team.

Dr Richard Seabrook, Head of Business Development at the Wellcome Trust, said: “We are pleased to be co-funding with the Bill & Melinda Gates Foundation on this exciting UK project, bringing together internationally renowned experts in the biology of infectious diseases with a first-class drug discovery unit to tackle some of the world’s most profound medical needs.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Professor Sir Philip Cohen Receives MRC Millennium Medal
Professor Sir Gregory Winter of the University of Cambridge also receives medal from MRC.
Friday, March 01, 2013
Dundee researchers and European collaborators find that anti-diabetes drug fights Alzheimer’s
A potentially exciting breakthrough in the treatment and prevention of Alzheimer’s disease has been made by researchers at the University of Dundee and their international collaborators.
Thursday, November 25, 2010
Drug Discovery Unit, University of Dundee, and DNDi Collaborate to Identify Drug Candidates to Treat Visceral Leishmaniasis
The £1.8m collaboration focuses on the discovery and development of affordable and effective therapies for the disease.
Tuesday, June 30, 2009
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!